Double-blind Comparative Study of TAK-875

The purpose of this study is to evaluate the efficacy and safety of treatment with TAK-875 in diabetic patients.

Completed

Looking for future studies?

Key information

Conditions

Diabetes Mellitus Endocrine System Diseases Glucose Metabolism Disorders Metabolic Diseases Nutritional and Metabolic Diseases

Age range

20 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 3

Primary location

Kisarazu-shi, Chiba, Japan

Who can participate

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

The participant is an outpatient.
The participant signs and dates a written, informed consent form and any required privacy authorization prior to the initiation of any study procedures.

Exclusion criteria

The participant has any serious cardiac disease, serious cerebrovascular disorder, or any serious pancreatic or hematological disease.
The participant is considered ineligible for the study for any other reason by the investigator or sub-investigator.

Treatment and study plan

TAK-875

Drug

Placebo

Drug

Primary outcomes

HbA1c

Sponsors and collaborators

Lead sponsor

Takeda

Industry

Registry information

Important dates

Primary completion: 2012
Study completion: 2012
First posted: Sep 14, 2011
Registry last updated: Nov 9, 2012

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed